Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gause, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gause, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: 13-16
© 2003 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Progress in the treatment of rheumatic disease

Angela Gause

Department of Rheumatology, University of Lübeck, D-23538 Lübeck, Germany

Keywords: COX2 inhibitors; IL-1-receptor antagonist; rheumatic disease; TNF{alpha} neutralizing substances

The first 150 words of the full text of this article appear below.

Introduction

The progress in defining the immunological and inflammatory mechanisms that lead to the progressive joint destruction in rheumatoid arthritis (RA) [1,2] has led to the development of new inhibitory drugs. Large randomized controlled trials have shown the efficacy of the new treatments and led to the recent approval of several new drugs by American and European health authorities. These are the COX2 inhibitors rofecoxib and celecoxib, the anti-metabolite leflunomide, and the ‘biologicals’, the TNF{alpha} neutralizing substances etanercept and infliximab and the IL1-receptor antagonist anakinra. At the same time, epidemiological investigations have started to describe the socio-economic consequences of inflammatory joint diseases, which often start at a young age and lead to retirement in 50% of the patients in the initial 3 years of the disease [3]. Analysing the outcome of patients with RA, responsive or not to methotrexate (MTX) treatment, it could be shown . . . [Full Text of this Article]

Cox2 inhibitors in the treatment of rheumatic disease

Standard therapy and combination therapy of RA

Leflunomide

TNF{alpha} neutralizing substances

Immuno-adsorption

IL-1-receptor antagonist and further perspectives

Conclusions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
M. L. Bell, G. K. Grunwald, J. H. Baltz, G. O. McDonald, M. R. Bell, F. L. Grover, and A. L. W. Shroyer
Does Preoperative Hemoglobin Independently Predict Short-Term Outcomes After Coronary Artery Bypass Graft Surgery?
Ann. Thorac. Surg., November 1, 2008; 86(5): 1415 - 1423.
[Abstract] [Full Text] [PDF]